A detailed history of Rhumbline Advisers transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 48,845 shares of BDTX stock, worth $118,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares
48,845
Previous 46,850 4.26%
Holding current value
$118,204
Previous $218,000 2.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.2 - $6.58 $8,379 - $13,127
1,995 Added 4.26%
48,845 $212,000
Q2 2024

Aug 01, 2024

BUY
$4.65 - $7.39 $215,764 - $342,903
46,401 Added 10334.3%
46,850 $218,000
Q2 2023

Aug 08, 2023

BUY
$1.43 - $6.18 $642 - $2,774
449 New
449 $2,000
Q2 2022

Aug 11, 2022

SELL
$1.5 - $3.63 $43,596 - $105,502
-29,064 Closed
0 $0
Q1 2022

May 12, 2022

SELL
$2.66 - $5.61 $4,652 - $9,811
-1,749 Reduced 5.68%
29,064 $81,000
Q4 2021

Feb 10, 2022

SELL
$5.18 - $8.48 $3,004 - $4,918
-580 Reduced 1.85%
30,813 $164,000
Q3 2021

Nov 12, 2021

BUY
$8.46 - $12.42 $9,094 - $13,351
1,075 Added 3.55%
31,393 $266,000
Q2 2021

Aug 05, 2021

BUY
$12.19 - $28.17 $146,426 - $338,378
12,012 Added 65.62%
30,318 $370,000
Q1 2021

May 06, 2021

SELL
$22.23 - $34.75 $24,564 - $38,398
-1,105 Reduced 5.69%
18,306 $444,000
Q4 2020

Feb 10, 2021

BUY
$29.47 - $35.0 $70,492 - $83,720
2,392 Added 14.05%
19,411 $622,000
Q3 2020

Nov 12, 2020

BUY
$26.17 - $43.07 $49,173 - $80,928
1,879 Added 12.41%
17,019 $514,000
Q2 2020

Aug 13, 2020

BUY
$22.3 - $44.8 $68,661 - $137,939
3,079 Added 25.53%
15,140 $638,000
Q1 2020

May 06, 2020

BUY
$18.18 - $39.48 $219,268 - $476,168
12,061 New
12,061 $301,000

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $87.9M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.